Heterocyclic oxime compounds

A compound of formula (I):

• or a pharmaceutically acceptable salt thereof,
• wherein
• Y is C or N;
• X is CH;
• B is N;
• A is a ring;
• such that when X is CH and B is N, ring A is ring Ai or ring Aii;
• R1 is a group i:
• wherein R5 is heteroaryl1,
• R6 is hydrogen, OH, methyl or halo;
• R7 is hydrogen, halo, or (C1-C3)alkyl, wherein said (C1-C3)alkyl is optionally substituted by one or more substituents independently selected from OH and halo;
• or R6 and R7, together with the carbon to which they are attached, form cyclopropyl;
• R2 is hydrogen, NH2, or (C1-C4)alkyl, wherein said (C1-C4)alkyl is optionally substituted by one or more substituents independently selected from OH, NH3 and halo;
• and R3 is (C1-C6)alkyl, wherein said (C1-C6)alkyl is optionally substituted by one or more substituents independently selected from halo, hydroxy and (C1-C3)alkoxy;
• heterocyclyl1;
• phenyl, wherein said phenyl is optionally substituted by one or more substituents independently selected from halo, hydroxy, (C1-C3)alkyl and (C1-C3)alkoxy, wherein said (C1-C3)alkyl and (C1-C3)alkoxy are each optionally substituted by one or more halo substituents;
• —CH2— heterocyclyl1;
• —CH2-phenyl, wherein the phenyl of said —CH2-phenyl is optionally substituted by one or more substituents independently selected from halo, hydroxy, (C1-C3)alkyl and (C1-C3)alkoxy, wherein said (C1-C3)alkyl and (C1-C3)alkoxy are each optionally substituted by one or more halo substituents;
• (C1-C4)alkylCO2(C1-C2)alkyl;
• (C0-C4)alkylCONH2;
• (C1-C4)alkylNH2;
• (C1-C4)alkylNHCONH2;
• (C1-C4)alkylCO2H;
• (C1-C4)alkylNHCO2CH3;
• —(C0-C4)alkyl(C3-C6)cycloalkyl or —(C0-C4)alkyl(C4-C6)cycloalkenyl;
• or hydrogen;
• heteroaryl1 is a 9- or 10-membered, unsaturated or partially unsaturated bicyclic group comprising 1, 2, 3 or 4 ring heteroatoms independently selected from N, O and S, wherein the total number of ring S atoms does not exceed 1, and the total number of ring O atoms does not exceed 1, and wherein heteroaryl1 is optionally substituted by one or more substituents independently selected from:
• halo;
• OH;
• (C1-C3)alkyl, said (C1-C3)alkyl being optionally substituted by one or more substituents independently selected from OH and halo;
• heterocyclyl2;
• and —C(CH3)═NO(C1-C3)alkyl, wherein the (C1-C3)alkyl of said C(CH3)═NO(C1-C3)alkyl is optionally substituted by one or more substituents independently selected from OH and halo;
• heterocyclyl1 is a 4, 5 or 6 membered saturated or partially unsaturated monocyclic group comprising 1 or 2 ring heteroatoms independently selected from N, O and S, and wherein heterocyclyl1 is optionally substituted by CONH2 or (C1-C3)alkyl;
• and heterocyclyl2 is a 5 or 6 membered saturated, unsaturated or partially unsaturated monocyclic group comprising 1, 2 or 3 ring heteroatoms independently selected from N, O and S, wherein the total number of ring S atoms does not exceed 1, and the total number of ring O atoms does not exceed 1, and heterocyclyl2 is optionally substituted by (C1-C3)alkyl.